Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; ...

Following completion of the ongoing Phase 2a proof-of-pharmacology study with BMB-101, Bright Minds plans to select and ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associa ...

Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its third quarter 2025 financial results and recent business activities. Participants may register ...

Q3 2025 Earnings Call Transcript November 13, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associa ...

Parenting hardly ever works out the way we picture it. Most of us think about tidy meals, calm kids, and days that kind of go ...

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its ...

NEW YORK/VANCOUVER - Bright Minds Biosciences Inc. (NASDAQ:DRUG) announced today the launch of its Prader-Willi Syndrome (PWS) program and the nomination of BMB-105 as a new clinical candidate. The ...